Product Description
CP-690,550 is a potent and selective JAK inhibitor currently in clinical trials for rheumatoid arthritis (RA) and other autoimmune disease indications. In enzyme assays it potently inhibited recombinant human kinase protein JAK1 (IC50=3.2nM), JAK2 (IC50=4.1nM) and JAK3 (IC50=1.6nM), but in cellular assays it potently inhibited signaling through JAK1 and JAK3 with 5-100 fold selectivity over JAK2.
Technical information:
| Chemical Formula: | C16H20N6O | |
| CAS #: | 477600-75-2 | |
| Molecular Weight: | 312.38 | |
| Purity: | >98% | |
| Appearance: | White solid | |
| Chemical Name: | 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile | |
| Solubility: | Up to 100 mM in DMSO |
Shipping Condition: The product is shipped in a glass vial at ambient temperature. Storage: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.
Reference:
| 1. | Meyer DM, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond). 2010 11;7:41. |
| 2. | Flanagan ME, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem. 2010 53(24):8468-84 |
